AstraZeneca receives FDA approval for Bydureon diabetes treatment

3rd Mar 2014 07:14

The US Food and Drug Administration (FDA) has approved AstraZeneca's injectable treatment for type 2 diabetes, the pharmaceutical company announced on Monday.Bydureon Pen, the first and only once-weekly medicine for adults with type 2 diabetes, has been given the green light as a supplement to diet and exercise to improve glycaemic control in adults with the condition."We're pleased to receive approval for the Bydureon Pen, which can provide a powerful reduction in blood glucose levels along with the potential benefit of weight loss, through a once-weekly dose in a pre-filled device," said Briggs Morrison, Executive Vice President of Global Medicines Development and Chief Medical Officer of AstraZeneca. "We are committed to addressing the needs of adults with type 2 diabetes, including ongoing research to develop new treatments and methods of delivery." BC